NDA 021406 · Upsher Smith Labs
Fortical
Calcitonin Salmon Recombinant · Nasal
DiscontinuedLast checked: Nov 20, 2026Latest source record: Sep 16, 2014 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2005
Aug 12, 2005
Approved uses
1
Original approval plus efficacy supplements
Registered trials
5
1 Phase 3, 0 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- FORTICAL · CALCITONIN SALMON RECOMBINANT 200 IU/SPRAY **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · SPRAY, METERED, NASAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Calcitonin Salmon Recombinant" as an intervention, any sponsor and status, largest first.
- A Study Comparing Oral Calcitonin to Nasal Spray Calcitonin in Postmenopausal Osteoporotic WomenPivotal-lookingCompleted
Tarsa Therapeutics, Inc.Industry
NCT00959764 · 565 participants · Start Jun 2009 · Primary completion Feb 2011
Drug: Oral Calcitonin Tablets; Intranasal Calcitonin and 1 more · For: Osteoporosis, Postmenopausal
Sites: Huntsville, Alabama; Oakland, California; Palm Desert, California · 20 sites in all
- A Study of Oral Recombinant Salmon Calcitonin (rsCT) to Prevent Postmenopausal OsteoporosisPivotal-lookingCompleted
Tarsa Therapeutics, Inc.Industry
NCT01292187 · 129 participants · Start Jan 2011 · Primary completion May 2012
Drug: Oral calcitonin at dinnertime; Oral placebo at dinnertime and 2 more · For: Osteopenia
Sites: Walnut Creek, California; Clearwater, Florida; Bethesda, Maryland · 10 sites in all
NantCell, Inc.Industry
NCT01856920 · 35 participants · Start Mar 26, 2013 · Primary completion May 8, 2018
Drug: GI-6207 [Recombinant Saccharomyces cerevisiae-CEA (610D)] · For: Medullary Thyroid Cancer (MTC)
Sites: Bethesda, Maryland
Tarsa Therapeutics, Inc.Industry
NCT00620854 · 24 participants · Start Feb 2008 · Primary completion Apr 2008
Drug: Recombinant Salmon Calcitonin (rsCT); Oral Tablet and 2 more · For: Osteoporosis
Sites: Springfield, Missouri
Tarsa Therapeutics, Inc.Industry
NCT00803686 · 12 participants · Start Dec 2008 · Primary completion Jan 2009
Drug: Oral rsCT tablet; Oral Placebo Tablet and 2 more · For: Phase 1 Pharmacodynamic Study
Sites: Springfield, Missouri
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
No PubMed clinical studies matched.
Sponsor: Upsher Smith Labs
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.